MEDP vs. PRAH, LH, EXEL, SYNH, IQV, ICLR, INCY, CRL, NRC, and OABI
Should you be buying Medpace stock or one of its competitors? The main competitors of Medpace include PRA Health Sciences (PRAH), Laboratory Co. of America (LH), Exelixis (EXEL), Syneos Health (SYNH), IQVIA (IQV), ICON Public (ICLR), Incyte (INCY), Charles River Laboratories International (CRL), National Research (NRC), and OmniAb (OABI).
PRA Health Sciences (NASDAQ:PRAH) and Medpace (NASDAQ:MEDP) are both large-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their community ranking, valuation, dividends, institutional ownership, risk, media sentiment, profitability, analyst recommendations and earnings.
In the previous week, Medpace had 9 more articles in the media than PRA Health Sciences. MarketBeat recorded 9 mentions for Medpace and 0 mentions for PRA Health Sciences. PRA Health Sciences' average media sentiment score of 1.16 beat Medpace's score of 0.00 indicating that Medpace is being referred to more favorably in the news media.
Medpace has a consensus price target of $443.14, suggesting a potential upside of 10.46%. Given PRA Health Sciences' higher possible upside, analysts clearly believe Medpace is more favorable than PRA Health Sciences.
Medpace has lower revenue, but higher earnings than PRA Health Sciences. Medpace is trading at a lower price-to-earnings ratio than PRA Health Sciences, indicating that it is currently the more affordable of the two stocks.
93.9% of PRA Health Sciences shares are owned by institutional investors. Comparatively, 78.0% of Medpace shares are owned by institutional investors. 1.3% of PRA Health Sciences shares are owned by company insiders. Comparatively, 20.3% of Medpace shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Medpace has a net margin of 15.92% compared to Medpace's net margin of 6.40%. PRA Health Sciences' return on equity of 59.74% beat Medpace's return on equity.
PRA Health Sciences has a beta of 1.31, meaning that its share price is 31% more volatile than the S&P 500. Comparatively, Medpace has a beta of 1.39, meaning that its share price is 39% more volatile than the S&P 500.
PRA Health Sciences received 29 more outperform votes than Medpace when rated by MarketBeat users. However, 64.02% of users gave Medpace an outperform vote while only 56.37% of users gave PRA Health Sciences an outperform vote.
Summary
Medpace beats PRA Health Sciences on 13 of the 17 factors compared between the two stocks.
Get Medpace News Delivered to You Automatically
Sign up to receive the latest news and ratings for MEDP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MEDP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
